1. Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction: The EXAMI study
- Author
-
Weena J.Y. Chen, Aernout M. Beek, Pieter A. Doevendans, Flip J.P. Bernink, Yolande Appelman, Leo Timmers, Niels van Royen, Otto Kamp, Martijn Scholte, Robert N. Denham, Koen M. Marques, Albert C. van Rossum, Michaela Diamant, Anton J.G. Horrevoets, Cardiology, Clinical pharmacology and pharmacy, Internal medicine, Molecular cell biology and Immunology, and ICaR - Heartfailure and pulmonary arterial hypertension
- Subjects
Glucagon-like peptide-1 ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Treatment outcome ,Myocardial Infarction ,Acute myocardial infarction ,Percutaneous Coronary Intervention ,Glucagon-Like Peptide 1 ,Internal medicine ,medicine ,Humans ,In patient ,Myocardial infarction ,Aged ,business.industry ,Venoms ,Follow up studies ,Percutaneous coronary intervention ,Middle Aged ,medicine.disease ,Reperfusion injury ,Treatment Outcome ,Cardiology ,Exenatide ,Feasibility Studies ,Administration, Intravenous ,Female ,business ,Peptides ,Cardiology and Cardiovascular Medicine ,medicine.drug ,Follow-Up Studies - Published
- 2013